Exclusive Summary

• - ICS/LABA is a standard-of-care for moderate asthma and selected COPD; the 250/50 dose is widely used globally.
• - Originator and device patents have expired; generics exist in the EU/US, and planned EU/Philippines filings in 2026 enable timely entry.
• - There is a large addressable base (≈262M asthma and ≈391M COPD globally), and DPI improves convenience and adherence across markets.
• - Expected 30–60% price discount vs originator plus reliable supply can win tenders and retail share in EU, Southeast Asia, and LATAM.
• - Distribution-ready model with device training/patient support can drive substitution and rapid uptake.